National Centre for Pharmacoeconomics

National Centre for

NCPE Ireland

Mogamulizumab (Poteligeo®). HTA ID: 20061

Mogamulizumab (Poteligeo®) is indicated for the treatment of adult patients with mycosis fungoides or Sézary syndrome who have received at least one prior systemic therapy.


NCPE Assessment Process Complete
Rapid review commissioned 21/12/2020
Rapid review completed 14/01/2021
Rapid Review outcome A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of mogamulizumab (Poteligeo®) compared with the current standard of care.
Full pharmacoeconomic assessment commissioned by HSE 27/01/2021
Pre-submission consultation with Applicant 23/03/2021
Current Status Awaiting HTA submission from Applicant